Prevalence and clinical significance of potential drug-drug interactions in diabetic patients attended in a tertiary care outpatient center, Brazil

  • Danilo D. TrevisanEmail author
  • Juliana B. Silva
  • Valéria C. Póvoa
  • Carla P. Araujo
  • Henrique C. Oliveira
  • Eliana P Araújo
  • Silvia R. Secoli
  • Maria Helena M. Lima
Original Article


The aim of this study is to investigate the prevalence of potential drug-drug interactions (PDDIs), as well as classifying them in relation to level of severity, scientific evidence, time of onset, and potential clinical impact in adult and older adult patients with diabetes mellitus 2 (DM2). This cross-sectional study was conducted in a tertiary care outpatient center. The consecutive sample was made up of 140 patients with DM2. The Anatomical-Therapeutic-Chemical Classification was used for classifying the classes of medications. The PDDIs were analyzed using the DRUG-REAX® system. The relationships between PDDI and the associated factors were ascertained using a multiple logistic regression model. The prevalence of total PDDI was 75 %, and the prevalence of major severity PDDI was 20.7 %. Simvastatin (30.8 %), captopril/enalapril (12.8 %), and oral anti-diabetics/insulin (12.8 %) were the medications which were most involved in the major PDDI, bringing relevant potential clinical impacts such as rhabdomyolysis, hyperkalemia, and important glycemic alterations. Polypharmacy was associated with PDDI (adjusted odds ratio = 10.46, 95 % confidence interval = 4.10–26.71). Diabetics were highly exposed to clinically significant PDDI. It is important that health professionals should be aware of the risks related to PDDI, so that measures may be implemented in order to assure safe care for the patient.


Diabetes mellitus Type 2 diabetes Drug interactions Tertiary healthcare Nursing 




Conflicts of interest

The authors declare that they have no competing interests.


  1. 1.
    World Health Organization. Global Status Report on Non-Communicable Diseases 2010 (2011). Accessed 09 Feb 2014.
  2. 2.
    Feng P, Wang X, Hu Z, Ma Y, Tang W, et al. Distribution and determinants of non communicable diseases among elderly Uyghur ethnic group in Xinjiang, China. PLoS One. 2014;9:e105536.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–71.CrossRefGoogle Scholar
  4. 4.
    American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36:S11–66.CrossRefGoogle Scholar
  5. 5.
    American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S14–80.CrossRefGoogle Scholar
  6. 6.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Freeman JS, Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol. 2012;5:31–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Secoli SR, Figueras A, Lebrao ML, de Lima FD, Santos JL. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27:759–70.CrossRefPubMedGoogle Scholar
  9. 9.
    JJV T, MTL C, Dos Santos CA, Romano-Lieber NS. Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, Southern Brazil. PLoS One. 2012;7:e47062.CrossRefGoogle Scholar
  10. 10.
    Bachmann KA. Drug interactions handbook.Hudson,: Lexi-Comp; 2003.Google Scholar
  11. 11.
    Tatro DS. Drug interactions facts. St Louis: Wolters Kluwer Health/Facts & Comparisons; 2011.Google Scholar
  12. 12.
    Van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RHJ, Burger DM, et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013; 108:1071–108.Google Scholar
  13. 13.
    Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther. 2004;76:85–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003;21:153–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Codagnone Neto V, Garcia VP, Santa Helena ET. Possible pharmacological interactions in hypertensive and/or diabetic elderly in family health units at Blumenau (SC). Braz J Pharm Sci. 2010;46:795–804.CrossRefGoogle Scholar
  16. 16.
    Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MH. Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2015;75:393–400.CrossRefPubMedGoogle Scholar
  17. 17.
    Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther. 2008;33:141–51.CrossRefPubMedGoogle Scholar
  18. 18.
    Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38:504–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Dinesh KU, Subish P, Pranaya M, Shankar PR, Anil SK, Durga B. Pattern of potential drug-drug interactions in diabetic out-patients in a tertiary care teaching hospital in Nepal. Med J Malays. 2007;62:294–8.Google Scholar
  20. 20.
    World Health Organization. Collaborating Center for Drug Statistics Methodology – ATC/DDD Index (2012). Accessed 06 Feb 2014.
  21. 21.
    Thomson Reuters Inc. (2012–2015). Micromedex® Healthcare Series. [Database]. Accessed 17 Feb 2014.
  22. 22.
    Hosmer Jr DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Willey & Sons; 2000.CrossRefGoogle Scholar
  23. 23.
    Chiang HH, Tseng FY, Wang CY, Chen CL, Chen YC, See TT, et al. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS One, 2014; 9:e109501.Google Scholar
  24. 24.
    Secoli SR, Danzi NJ, Ferreira de Lima FF, Lorenzi Filho G, Cesar LAM. Drug interactions in patients with coronary artery disease. Rev Bras Cartogr. 2012;25:11–8.Google Scholar
  25. 25.
    Doubova SV, Reyes-Morales H, Torres-Arreola LP, Suarez-Ortega M Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.CrossRefGoogle Scholar
  26. 26.
    Marquito AB, Fernandes NMS, Basile Colugnati FA, de Paula RB. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014;36:26–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Patel PS, Rana DA, Suthar JV, Malhotra SD, Patel VJ. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. J Basic Clin Pharm. 2014;5:44–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    De Araújo MF, Dos Santos Alves PJ, Veras VS, de Araújo TM, Zanetti ML, Damasceno MM. Drug interactions in Brazilian type 2 diabetes patients. Int J Nurs Pract. 2013;19:423–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefGoogle Scholar
  30. 30.
    Borders-Hemphill V. Concurrent use of statins and amiodarone. Consult Pharm. 2009;24:372–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Tuchscherer RM, Nair K, Ghushchyan V, Saseen JJ. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Am J Cardiovasc Drugs. 2015;15:27–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33:171–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening Hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438–41.CrossRefPubMedGoogle Scholar
  34. 34.
    Eschmann E, Beeler PE, Kaplan V, Schneemann M, Zünd G, Blaser J. Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug-drug interactions. Eur J Clin Pharmacol. 2014;70:215–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther. 2010;88:214–22.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Micheli L, Sbrilli M, Nencini C. Severe hypoglycemia associated with levofloxacin in type 2 diabetic patients receiving polytherapy: two case reports. Int J Clin Pharmacol Ther. 2012;50:302–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Paris B, Yerino P, Ogilvie B, Parkinson A. Abstract 130: the proton pump inhibitors (PPIs) omeprazole and rabeprazole but not lansoprazole and pantoprazole are in vitro time-dependent inhibitors of CYP2C19. Drug Metab Rev. 2008;40:89–90.Google Scholar
  38. 38.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010;96:186–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557–63.CrossRefPubMedGoogle Scholar
  40. 40.
    Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv. 2012;5:77–81.CrossRefPubMedGoogle Scholar
  41. 41.
    Olesen JB, Gislason GH, Charlot MG, Fosbøl EL, Andersson C, Weeke P, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol. 2011;57:409–17.CrossRefPubMedGoogle Scholar
  42. 42.
    Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009;16:40–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2015

Authors and Affiliations

  • Danilo D. Trevisan
    • 1
    Email author
  • Juliana B. Silva
    • 1
    • 2
  • Valéria C. Póvoa
    • 2
  • Carla P. Araujo
    • 1
  • Henrique C. Oliveira
    • 1
  • Eliana P Araújo
    • 1
  • Silvia R. Secoli
    • 2
  • Maria Helena M. Lima
    • 1
  1. 1.Faculty of NursingUniversity of CampinasSão PauloBrazil
  2. 2.School of NursingUniversity of São PauloSão PauloBrazil

Personalised recommendations